Intra-Cellular Therapies Company Profile (NASDAQ:ITCI)

About Intra-Cellular Therapies (NASDAQ:ITCI)

Intra-Cellular Therapies logoIntra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company's bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer's Disease (AD).

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $835.91 million
  • Outstanding Shares: 43,424,000
Average Prices:
  • 50 Day Moving Avg: $15.29
  • 200 Day Moving Avg: $13.12
  • 52 Week Range: $7.85 - $44.19
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.64
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $312,285.00
  • Price / Sales: 2,676.76
  • Book Value: $7.82 per share
  • Price / Book: 2.46
Profitability:
  • EBIDTA: ($104,390,000.00)
  • Net Margins: -32,834.94%
  • Return on Equity: -27.92%
  • Return on Assets: -24.79%
Debt:
  • Current Ratio: 50.12%
  • Quick Ratio: 50.12%
Misc:
  • Average Volume: 579,056 shs.
  • Beta: 0.8
  • Short Ratio: 22.2
 

Frequently Asked Questions for Intra-Cellular Therapies (NASDAQ:ITCI)

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies Inc. (NASDAQ:ITCI) posted its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.41) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.74) by $0.33. The business had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.03 million. Intra-Cellular Therapies had a negative return on equity of 27.92% and a negative net margin of 32,834.94%. The company's quarterly revenue was down 52.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.71) EPS. View Intra-Cellular Therapies' Earnings History.

When will Intra-Cellular Therapies make its next earnings announcement?

Intra-Cellular Therapies is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Intra-Cellular Therapies.

Where is Intra-Cellular Therapies' stock going? Where will Intra-Cellular Therapies' stock price be in 2017?

9 analysts have issued 1 year price objectives for Intra-Cellular Therapies' stock. Their predictions range from $12.00 to $49.00. On average, they anticipate Intra-Cellular Therapies' stock price to reach $29.00 in the next year. View Analyst Ratings for Intra-Cellular Therapies.

What are analysts saying about Intra-Cellular Therapies stock?

Here are some recent quotes from research analysts about Intra-Cellular Therapies stock:

  • 1. Cowen and Company analysts commented, "This AM, ITCI disclosed FDA had agreed lumateperone preclinical dog tox signals." (8/23/2017)
  • 2. According to Zacks Investment Research, "Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York. " (8/15/2017)
  • 3. Cantor Fitzgerald analysts commented, "Investors may be waiting for Godot (the FDA). We spoke with ITCI management this morning in conjunction with the release of 2Q17 results (no call was held). They noted that the company has responded to FDA questions regarding the non-clinical toxicology findings. Perhaps off-putting to investors, but consistent with the manner in which the FDA handles such issues, ITCI is challenged in providing any time-line along which the situation could be resolved." (8/9/2017)
  • 4. Piper Jaffray Companies analysts commented, "With Intra-Cellular's 4Q16 call set for Weds., 3/1, we're refreshing our thesis and outlining potential outcomes of this business update. Given the 5 months since data, we'll look for visibility on four key issues: 1. Data-driven insight into factors contributing to the 302 trial failure; 2. Preliminary feedback from the FDA on the 302 trial and lumateperone (ITI-007) program; 3. The clinical and regulatory path forward for luma' over the next 12-18 months; 4. Cash required to execute on these plans." (2/23/2017)

Who are some of Intra-Cellular Therapies' key competitors?

Who are Intra-Cellular Therapies' key executives?

Intra-Cellular Therapies' management team includes the folowing people:

  • Lawrence J. Hineline CPA, Chief Financial Officer, Vice President - Finance, Treasurer, Assistant Secretary
  • Robert E. Davis Ph.D., Senior Vice President and Chief Scientific Officer
  • Michael I. Halstead, Senior Vice President, General Counsel, Secretary
  • Kimberly E. Vanover Ph.D., Senior Vice President, Clinical Development
  • Juan F. Sanchez M.D., Vice President - Corporate Communications
  • Allen A. Fienberg Ph.D., Vice President - Business Development
  • Sharon Mates Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Christopher D. Alafi Ph.D., Independent Director
  • Richard Alan Lerner M.D., Independent Director
  • Joel S. Marcus J.D. CPA, Independent Director

Who owns Intra-Cellular Therapies stock?

Intra-Cellular Therapies' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Vanguard Group Inc. (6.27%), BB BIOTECH AG (5.10%), BB Biotech AG (4.95%), Wasatch Advisors Inc. (3.82%) and State Street Corp (2.31%). Company insiders that own Intra-Cellular Therapies stock include Alafi Capital Co Llc, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Michael Halstead and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies.

Who sold Intra-Cellular Therapies stock? Who is selling Intra-Cellular Therapies stock?

Intra-Cellular Therapies' stock was sold by a variety of institutional investors in the last quarter, including Numeric Investors LLC, Wells Fargo & Company MN, Candriam Luxembourg S.C.A., TIAA CREF Investment Management LLC, Vanguard Group Inc., Northern Trust Corp, PDT Partners LLC and Franklin Street Advisors Inc. NC. Company insiders that have sold Intra-Cellular Therapies stock in the last year include Kimberly E Vanover, Lawrence J Hineline, Michael Halstead and Sharon Mates. View Insider Buying and Selling for Intra-Cellular Therapies.

Who bought Intra-Cellular Therapies stock? Who is buying Intra-Cellular Therapies stock?

Intra-Cellular Therapies' stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Dimensional Fund Advisors LP, Goldman Sachs Group Inc., BB Biotech AG, Samlyn Capital LLC, Federated Investors Inc. PA, State Street Corp and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have bought Intra-Cellular Therapies stock in the last two years include Alafi Capital Co Llc and Christopher D Alafi. View Insider Buying and Selling for Intra-Cellular Therapies.

How do I buy Intra-Cellular Therapies stock?

Shares of Intra-Cellular Therapies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intra-Cellular Therapies' stock price today?

One share of Intra-Cellular Therapies stock can currently be purchased for approximately $19.25.


MarketBeat Community Rating for Intra-Cellular Therapies (NASDAQ ITCI)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  237 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  345
MarketBeat's community ratings are surveys of what our community members think about Intra-Cellular Therapies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Intra-Cellular Therapies (NASDAQ:ITCI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.78)
Consensus Price Target: $29.00 (50.65% upside)

Analysts' Ratings History for Intra-Cellular Therapies (NASDAQ:ITCI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/8/2017BTIG ResearchReiterated RatingBuy$36.00MediumView Rating Details
9/8/2017SunTrust Banks, Inc.Reiterated RatingHold$16.00 -> $22.00LowView Rating Details
9/8/2017Cowen and CompanyReiterated RatingOutperform$20.00 -> $27.00MediumView Rating Details
9/7/2017Piper Jaffray CompaniesUpgradeNeutral -> Overweight$14.00 -> $33.00HighView Rating Details
8/24/2017JMP SecuritiesUpgradeMarket Perform -> Outperform$24.00HighView Rating Details
8/23/2017Leerink SwannUpgradeMarket Perform -> OutperformHighView Rating Details
8/9/2017Cantor FitzgeraldReiterated RatingBuyHighView Rating Details
5/2/2017Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralHighView Rating Details
9/30/2016Royal Bank Of CanadaReiterated RatingOutperform$74.00 -> $49.00N/AView Rating Details
9/29/2015GuggenheimBoost Price TargetBuy$95.00 -> $104.00N/AView Rating Details
(Data available from 9/22/2015 forward)

Earnings

Earnings History for Intra-Cellular Therapies (NASDAQ:ITCI)
Earnings by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)
Earnings History by Quarter for Intra-Cellular Therapies (NASDAQ ITCI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017        
8/9/2017Q2 2017($0.74)($0.41)$0.03 million$0.11 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.74)($0.62)$0.02 million$0.10 millionViewN/AView Earnings Details
3/1/2017Q4 2016($0.77)($0.64)$0.10 million$0.10 millionViewListenView Earnings Details
11/9/2016Q316($0.84)($0.70)$0.04 million$4.36 millionViewListenView Earnings Details
8/4/2016Q216($0.79)($0.71)$0.02 million$0.23 millionViewN/AView Earnings Details
4/28/2016Q116($0.78)($0.64)$0.02 millionViewListenView Earnings Details
2/25/2016Q415($0.84)($0.67)$0.05 million$30.66 millionViewListenView Earnings Details
11/5/2015Q315($0.66)($0.91)$0.10 millionViewN/AView Earnings Details
8/5/2015Q215($0.72)($0.61)$40.00 million$57.40 millionViewN/AView Earnings Details
4/30/2015Q1($0.68)($0.72)ViewN/AView Earnings Details
3/12/2015Q4 2014($0.49)($0.52)$0.07 millionViewN/AView Earnings Details
11/3/2014Q314($0.34)($0.22)$0.12 millionViewN/AView Earnings Details
8/12/2014Q214($0.24)($0.15)$0.22 millionViewN/AView Earnings Details
5/5/2014Q1 2014($0.23)($0.17)$0.17 millionViewN/AView Earnings Details
3/26/2014($0.41)($0.36)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Intra-Cellular Therapies (NASDAQ:ITCI)
2017 EPS Consensus Estimate: ($2.54)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.70)($0.69)($0.70)
Q2 20172($0.69)($0.65)($0.67)
Q3 20172($0.64)($0.48)($0.56)
Q4 20172($0.67)($0.55)($0.61)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Intra-Cellular Therapies (NASDAQ:ITCI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Intra-Cellular Therapies (NASDAQ:ITCI)
Insider Ownership Percentage: 19.80%
Institutional Ownership Percentage: 71.79%
Insider Trades by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)
Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)
Insider Trades by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/5/2017Lawrence J HinelineVPSell1,918$16.58$31,800.44View SEC Filing  
1/5/2017Michael HalsteadSVPSell1,601$16.55$26,496.55View SEC Filing  
1/5/2017Sharon MatesChairmanSell4,081$16.55$67,540.55View SEC Filing  
12/15/2016Kimberly E VanoverSVPSell9,375$15.23$142,781.25View SEC Filing  
12/7/2016Alafi Capital Co LlcMajor ShareholderBuy65,000$16.27$1,057,550.00View SEC Filing  
11/14/2016Christopher D AlafiDirectorBuy34,000$14.50$493,000.00View SEC Filing  
2/29/2016Christopher D AlafiDirectorBuy100,000$29.70$2,970,000.00View SEC Filing  
12/15/2015Lawrence J. HinelineCFOSell45,000$51.45$2,315,250.00View SEC Filing  
12/11/2015Sharon MatesCEOSell51,500$53.87$2,774,305.00View SEC Filing  
12/8/2015Joel S MarcusDirectorSell92,700$54.47$5,049,369.00View SEC Filing  
11/24/2015Lawrence J HinelineCFOSell5,000$55.00$275,000.00View SEC Filing  
6/8/2015Lawrence P WennogleVPSell25,000$26.84$671,000.00View SEC Filing  
3/11/2015Christopher D AlafiDirectorBuy625,000$24.00$15,000,000.00View SEC Filing  
12/9/2014Lawrence J HinelineCFOSell22,500$16.71$375,975.00View SEC Filing  
12/1/2014Moshe AlafiMajor ShareholderBuy1,422$14.75$20,974.50View SEC Filing  
11/28/2014Christopher D AlafiDirectorBuy35,000$14.75$516,250.00View SEC Filing  
11/19/2014Alafi Capital Co LlcMajor ShareholderBuy1,034$14.25$14,734.50View SEC Filing  
11/18/2014Alafi Capital Co LlcMajor ShareholderBuy3,664$14.26$52,248.64View SEC Filing  
11/13/2014Alafi Capital Co LlcMajor ShareholderBuy12,200$15.34$187,148.00View SEC Filing  
11/6/2014Michael HalsteadSVPBuy20,000$15.38$307,600.00View SEC Filing  
10/15/2014Lawrence P WennogleVPSell3,604$15.00$54,060.00View SEC Filing  
10/13/2014Lawrence P WennogleVPSell1,600$15.00$24,000.00View SEC Filing  
10/8/2014Lawrence P WennogleVPSell4,745$15.00$71,175.00View SEC Filing  
10/6/2014Lawrence P WennogleVPSell16,499$15.00$247,485.00View SEC Filing  
9/15/2014Lawrence P WennogleVPSell5,000$15.00$75,000.00View SEC Filing  
9/8/2014Lawrence J HinelineCFOSell300$15.00$4,500.00View SEC Filing  
5/22/2014Lawrence P WennogleVPSell6,000$15.00$90,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Intra-Cellular Therapies (NASDAQ:ITCI)
Latest Headlines for Intra-Cellular Therapies (NASDAQ:ITCI)
Source:
DateHeadline
globenewswire.com logoIntra-Cellular Therapies to Participate at Upcoming Investor Conferences - GlobeNewswire (press release)
globenewswire.com - September 19 at 12:32 AM
finance.yahoo.com logoIntra-Cellular Therapies to Participate at Upcoming Investor Conferences
finance.yahoo.com - September 18 at 7:28 PM
finance.yahoo.com logo3 Reasons Why Intra-Cellular Therapies (ITCI) is a Great Momentum Stock
finance.yahoo.com - September 11 at 8:55 PM
americanbankingnews.com logoSunTrust Banks Equities Analysts Cut Earnings Estimates for Intra-Cellular Therapies Inc. (ITCI)
www.americanbankingnews.com - September 11 at 9:42 AM
americanbankingnews.com logoIntra-Cellular Therapies Inc. (ITCI) Upgraded to "Overweight" at Piper Jaffray Companies
www.americanbankingnews.com - September 10 at 6:58 AM
americanbankingnews.com logoIntra-Cellular Therapies Inc. (ITCI) Stock Rating Reaffirmed by BTIG Research
www.americanbankingnews.com - September 9 at 12:32 AM
americanbankingnews.com logoIntra-Cellular Therapies' (ITCI) "Hold" Rating Reaffirmed at SunTrust Banks, Inc.
www.americanbankingnews.com - September 8 at 9:52 PM
americanbankingnews.com logoIntra-Cellular Therapies Inc. (ITCI) Receives Outperform Rating from Cowen and Company
www.americanbankingnews.com - September 8 at 8:42 PM
fool.com logoWhy Intra-Cellular Therapies Is Surging Today
www.fool.com - September 7 at 10:43 PM
feeds.benzinga.com logoIntra-Cellular Therapies Announces Positive Topline Data From 6-Week Open-label Safety Switching Study with Lumateperone in Patients with Schizophrenia
feeds.benzinga.com - September 7 at 8:20 AM
finance.yahoo.com logoWhy Intra-Cellular (ITCI) Could Be Positioned for a Surge
finance.yahoo.com - September 2 at 1:08 AM
finance.yahoo.com logoETFs with exposure to Intra-Cellular Therapies, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 8:02 PM
americanbankingnews.com logoIntra-Cellular Therapies Inc (ITCI) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 29 at 11:08 PM
americanbankingnews.com logoIntra-Cellular Therapies Inc. (ITCI) Forecasted to Earn FY2019 Earnings of ($2.34) Per Share
www.americanbankingnews.com - August 25 at 2:44 PM
nasdaq.com logoIntra-Cellular (ITCI) Soars: Stock Adds 27.7% in Session - Nasdaq
www.nasdaq.com - August 25 at 7:14 AM
finance.yahoo.com logoIntra-Cellular Therapies, Inc. :ITCI-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 7:14 AM
americanbankingnews.com logoPiper Jaffray Companies Reiterates "Hold" Rating for Intra-Cellular Therapies Inc. (ITCI)
www.americanbankingnews.com - August 24 at 5:06 PM
streetinsider.com logoIntra-Cellular Therapies (ITCI) Says Its Moving Forward with Long-Term Safety Study of Lumateperone to Treat Schizophrenia
www.streetinsider.com - August 24 at 8:07 AM
streetinsider.com logoIntra-Cellular Therapies (ITCI) Says Its Moving Forward with Long-Term Safety Study of Lumateperone to Treat Schizophrenia
www.streetinsider.com - August 24 at 8:07 AM
rttnews.com logoIntra-Cellular Therapies (ITCI) Has Jumped To A 4-Month High On FDA News
www.rttnews.com - August 24 at 8:07 AM
zacks.com logoIntra-Cellular (ITCI) Soars: Stock Adds 27.7% in Session
www.zacks.com - August 24 at 8:07 AM
finance.yahoo.com logoIntra-Cellular Therapies Announces Positive Regulatory Update On Schizophrenia Program
finance.yahoo.com - August 24 at 8:07 AM
finance.yahoo.com logoIntra-Cellular Therapies Announces Positive Regulatory Update On Schizophrenia Program
finance.yahoo.com - August 24 at 8:07 AM
finance.yahoo.com logoIntra-Cellular Soars on Critical FDA Update
finance.yahoo.com - August 24 at 8:07 AM
finance.yahoo.com logoIntra-Cellular Soars on Critical FDA Update
finance.yahoo.com - August 24 at 8:07 AM
finance.yahoo.com logoWhy Intra-Cellular Therapies Is Skyrocketing Today
finance.yahoo.com - August 24 at 8:07 AM
finance.yahoo.com logoWhy Fiat Chrysler Automobiles, Intra-Cellular Therapies, and Express Jumped Today
finance.yahoo.com - August 24 at 8:07 AM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: Intra-Cellular Therapies and Immune Pharmaceuticals
finance.yahoo.com - August 24 at 8:07 AM
americanbankingnews.com logoJMP Securities Upgrades Intra-Cellular Therapies Inc. (ITCI) to Outperform
www.americanbankingnews.com - August 24 at 8:06 AM
americanbankingnews.com logoIntra-Cellular Therapies' (ITCI) Buy Rating Reaffirmed at Cowen and Company
www.americanbankingnews.com - August 23 at 9:42 PM
americanbankingnews.com logoIntra-Cellular Therapies Inc. (ITCI) Upgraded to "Outperform" by Leerink Swann
www.americanbankingnews.com - August 23 at 11:50 AM
americanbankingnews.com logoIntra-Cellular Therapies Inc. (ITCI) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - August 18 at 11:28 PM
americanbankingnews.com logoIntra-Cellular Therapies Inc. Forecasted to Earn Q3 2017 Earnings of ($0.48) Per Share (ITCI)
www.americanbankingnews.com - August 17 at 8:28 AM
finance.yahoo.com logoIntra-Cellular Therapies, Inc. breached its 50 day moving average in a Bullish Manner : ITCI-US : August 15, 2017
finance.yahoo.com - August 16 at 1:58 AM
finance.yahoo.com logoIntra-Cellular Therapies, Inc. – Value Analysis (NASDAQ:ITCI) : August 15, 2017
finance.yahoo.com - August 16 at 1:58 AM
americanbankingnews.com logoIntra-Cellular Therapies Inc. (ITCI) Given Market Perform Rating at Leerink Swann
www.americanbankingnews.com - August 15 at 10:32 PM
americanbankingnews.com logoEquities Analysts Set Expectations for Intra-Cellular Therapies Inc.'s Q3 2017 Earnings (ITCI)
www.americanbankingnews.com - August 14 at 2:50 AM
finance.yahoo.com logoIntra-Cellular Therapies Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 9 at 9:24 PM
finance.yahoo.com logoIntra-Cellular reports 2Q loss
finance.yahoo.com - August 9 at 9:24 PM
americanbankingnews.com logoIntra-Cellular Therapies Inc. (ITCI) Releases Quarterly Earnings Results, Beats Expectations By $0.37 EPS
www.americanbankingnews.com - August 9 at 5:32 PM
americanbankingnews.com logoIntra-Cellular Therapies Inc. (NASDAQ:ITCI) Earns Buy Rating from Cantor Fitzgerald
www.americanbankingnews.com - August 9 at 4:40 PM
finance.yahoo.com logoWhy Minerva Neurosciences Inc. Fell 31.1% in July
finance.yahoo.com - August 7 at 7:26 PM
americanbankingnews.com logoIntra-Cellular Therapies Inc. (ITCI) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - August 5 at 2:24 PM
americanbankingnews.com logoIntra-Cellular Therapies Inc (ITCI) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 4 at 10:38 PM
finance.yahoo.com logoIntra-Cellular Therapies, Inc. breached its 50 day moving average in a Bearish Manner : ITCI-US : August 2, 2017
finance.yahoo.com - August 3 at 12:11 AM
americanbankingnews.com logoIntra-Cellular Therapies Inc. (NASDAQ:ITCI) Cut to Hold at BidaskClub
www.americanbankingnews.com - July 29 at 3:35 PM
seekingalpha.com logoIntra-Cellular Therapies: Buy, Sell Or Hold? - Seeking Alpha
seekingalpha.com - July 26 at 8:19 PM
nasdaq.com logoIntra-Cellular Therapies Presents at the 2017 International College of Neuro ...
www.nasdaq.com - July 21 at 5:07 AM
finance.yahoo.com logoIntra-Cellular Therapies Presents at the 2017 International College of Neuro-Psychopharmacology (CINP) Thematic Meeting on Treatment-Resistant Depression
finance.yahoo.com - July 21 at 12:06 AM
globenewswire.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Intra-Cellular ... - GlobeNewswire (press release)
globenewswire.com - July 13 at 3:35 AM

Social

Chart

Intra-Cellular Therapies (ITCI) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff